JSKN027

JSKN027 is a first-in-class bispecific antibody-drug conjugate (ADC) developed by Jiangsu Alphamab Biopharmaceuticals. It is engineered to simultaneously target Programmed cell death 1 ligand 1 (PD-L1) and Vascular endothelial growth factor receptor 2 (VEGFR2). The molecule utilizes glycan-specific conjugation technology to attach a cleavable linker and a topoisomerase I inhibitor payload to the antibody's Fc region. This design allows JSKN027 to exert a triple therapeutic effect: targeted cytotoxic chemotherapy, inhibition of tumor angiogenesis, and enhancement of the anti-tumor immune response. As of late 2025, the drug has entered Phase I clinical evaluation for patients with advanced malignant solid tumors, specifically focusing on colorectal cancer, non-small cell lung cancer, and hepatocellular carcinoma.